Analyst Comments on Gilead Sciences (GILD) P-II TAF Study

March 5, 2013 3:19 PM EST Send to a Friend
Get Alerts GILD Hot Sheet
Price: $100.58 -0.01%

Rating Summary:
    23 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade GILD Now!
Join SI Premium – FREE
This morning Gilead Sciences, Inc. (Nasdaq: GILD) announced detailed 24-week results from a Phase 2 study (Study 102) evaluating a once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection.

Commenting on the results, analyst at Wells Fargo said, "The detailed data clearly support the potential for TAF's bone and kidney advantages that could address the some of the shortcomings of Viread and make it a successful life cycle strategy, with very similar efficacy and a generally similar safety profile which will need to be confirmed in ph.III."

Wells Fargo has an Outperform rating on Gilead Sciences.

For an analyst ratings summary and ratings history on Gilead Sciences (Nasdaq: GILD) click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $43.87 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, FDA

Related Entities

Wells Fargo

Add Your Comment